Why earlier treatment changes the question you are asking
An oligodendroglioma is a glioma, and glioma care is not a single event. Assessment of an adult central nervous system tumour considers tumour type, site and grade along with the patient's circumstances, and treatment decisions are individual. That sentence matters for a second opinion because it tells you what the receiving team needs: not a general description of your diagnosis, but the specific history that produced your current situation.
A patient who has had surgery, then radiotherapy, then chemotherapy is asking a different question from a patient who has had a biopsy only. One may be asking whether further treatment is appropriate now. Another may be asking whether the original diagnosis and molecular profile are complete enough to plan anything at all. If you send the same summary to both, the team cannot tell which decision you need.
This is why 'earlier treatment' is not background colour. It is the clinical context that determines whether a Chinese neurosurgery or neuro-oncology team can offer a meaningful opinion. When that history arrives as a one-line diagnosis with no dates, no sequencing and no molecular addendum, the team can only respond in general terms, and a general reply rarely helps you decide anything.
The reports that carry the most weight: IDH and 1p/19q
For oligodendroglioma specifically, two molecular results are usually central to how the tumour is classified and discussed: IDH status and 1p/19q codeletion status. These are not optional extras. They are part of how a modern neuro-oncology team understands what type of glioma you have, and they influence how earlier treatment is interpreted.
The practical problem is that many patients hold a pathology report that predates current molecular testing, or a report that mentions IDH and 1p/19q in a supplementary page they have never read. If your earlier treatment was planned without those results, or if the results exist but were never integrated into the treatment summary, the receiving team is working with an incomplete picture.
Ask your treating hospital for the full pathology report, including any molecular or immunohistochemistry addendum, and for the block or slide availability if re-review is being considered. Do not assume the one-line diagnosis on a discharge letter is enough. If the molecular results genuinely do not exist, say so explicitly rather than leaving the question open, because that changes what the receiving team can conclude.
One caution: do not treat a molecular result as a treatment recommendation. IDH and 1p/19q status inform classification and discussion; they do not by themselves tell you what should happen next. That judgement belongs to the treating clinicians who can see the imaging, the operative notes and you.
Describing the sequence, not just the list of treatments
A common mistake in overseas enquiries is to list treatments without their order, dates or outcome. 'Surgery and radiotherapy' tells a team almost nothing. 'Biopsy in 2019, resection in 2020, radiotherapy completed in 2021, temozolomide stopped in 2022 because of a specific reason' tells them where you are in the disease course.
Sequencing matters because the same treatment means different things at different points. A resection performed before any radiotherapy is a different clinical event from a second resection after chemoradiation. A chemotherapy course stopped early for toxicity is different from one completed as planned. The receiving team needs to know which of these applies to you.
For each earlier treatment, try to record four things: what was done, when, at which hospital, and what the documented result or reason for stopping was. If a treatment was declined or deferred, that is also part of the history and worth stating plainly. If you do not know why something stopped, write 'reason not documented' rather than guessing.
Imaging is part of this sequence. Ask for the actual imaging files, not only the written reports, because a neurosurgery team reviewing a possible next step will want to compare scans over time. If you only have reports, say so, and ask what the receiving hospital would need.
Separating what is confirmed from what is still being verified
When you write to a Chinese hospital or a coordination service, distinguish clearly between confirmed facts and open questions. Confirmed: the diagnosis on the pathology report, the date of surgery, the name of the chemotherapy. Open: whether the molecular testing was complete, whether the original slides can be released, whether the last imaging was reviewed by a neuro-radiologist.
This distinction protects you. If you present an unverified detail as confirmed and the receiving team builds an opinion on it, the opinion may not apply to your real situation. If you flag it as unverified, the team can tell you what they need to resolve it.
It also makes the reply more useful. A team that knows your molecular results are missing can ask for them specifically. A team that assumes they exist may give a general answer that does not help you decide anything.
Write your summary in two columns if that helps: 'Confirmed by documents I hold' and 'To be confirmed with my treating hospital'. Keep it to one page. The goal is not completeness for its own sake; it is to let a clinician see quickly whether they can assess your case.
- Confirmed: diagnosis wording, dates, hospitals, treatments given, documented outcomes.
- To confirm: molecular addenda, slide or block availability, imaging files versus reports, reason for any stopped treatment.
- Not yet known: whether re-review is needed, what the receiving team requires, whether an in-person visit is necessary.
What a Chinese neurosurgery team can and cannot decide from records
A records-based review can help a team understand your history and indicate whether further assessment in China is worth considering. It cannot establish final eligibility for a procedure, confirm hospital acceptance or replace an in-person evaluation. Those are decisions for the treating hospital after it has what it needs.
For oligodendroglioma, the questions a team may want to address include whether the earlier treatment was appropriate for the molecular profile, whether further surgery or other treatment is being considered, and whether the imaging shows something that changes the picture. None of these can be answered responsibly from a partial file.
If you are considering travel to China for neurosurgical assessment, the relevant CSC reference is the glioma surgery page, which describes the procedure context. Use it to understand what the service covers, not as a substitute for the clinical conversation.
Be cautious about any service that offers a definitive plan before seeing your molecular reports and imaging. A responsible team will tell you what is missing. A team that does not ask is not giving you a records-based opinion; it is giving you a generic one.
A practical way to prepare your earlier-treatment summary
Start with a one-page chronology. Date, hospital, what was done, documented result. Then attach the pathology report with any molecular addendum, the operative notes if available, the radiotherapy summary, and the chemotherapy record including agents, cycles and reason for stopping. Add the most recent imaging reports and, if you can obtain them, the imaging files.
Then write three or four sentences stating your actual question. 'I was diagnosed with oligodendroglioma in 2019, had resection and radiotherapy, and my last scan showed a change. I want to know whether further surgery is being considered and what records you need.' That is more useful than a long narrative.
If you are working with a coordination service, ask what it will do with the records, who reviews them, and what the output will be. An initial enquiry is free and does not require buying a proxy consultation. The hospital decides suitability, and no service can promise acceptance or a particular outcome.
A brief next step: gather the pathology report including molecular results, the treatment chronology and the latest imaging, then send a short summary through the enquiry form. Ask specifically what is missing for a neurosurgery team to assess your earlier treatment. That single question will tell you more than a general request for a second opinion.
Sources & scope of this guide
References and official service information relevant to this guide.
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.